Vertex Pharmaceuticals Incorporated
VRTX
$477.89
$3.620.76%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 8.63% | 10.04% | 10.16% | 8.88% | 11.66% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8.90% | 10.33% | 10.46% | 8.98% | 11.66% |
| Cost of Revenue | 7.75% | 12.41% | 13.10% | 18.13% | 16.63% |
| Gross Profit | 9.92% | 8.53% | 8.18% | 1.60% | 7.63% |
| SG&A Expenses | 19.72% | 12.91% | 16.52% | 22.60% | 28.83% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.40% | 12.52% | 13.85% | 19.09% | 19.12% |
| Operating Income | 6.65% | 7.02% | 5.50% | -4.31% | 2.03% |
| Income Before Tax | 1,768.49% | 1,613.67% | 1,937.26% | -106.30% | -94.33% |
| Income Tax Expenses | -12.00% | 4.63% | 4.51% | -7.93% | 3.14% |
| Earnings from Continuing Operations | 838.09% | 865.96% | 842.52% | -124.60% | -114.80% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 838.09% | 865.96% | 842.52% | -124.60% | -114.80% |
| EBIT | 6.65% | 7.02% | 5.50% | -4.31% | 2.03% |
| EBITDA | 6.31% | 5.96% | 4.75% | -4.30% | 2.23% |
| EPS Basic | 848.27% | 872.78% | 847.05% | -124.45% | -114.72% |
| Normalized Basic EPS | 6.54% | 5.09% | 2.36% | -5.94% | 0.72% |
| EPS Diluted | 795.46% | 810.70% | 787.39% | -125.47% | -115.87% |
| Normalized Diluted EPS | 6.57% | 5.05% | 2.18% | -5.71% | 0.93% |
| Average Basic Shares Outstanding | -0.84% | -0.51% | -0.28% | -0.11% | 0.10% |
| Average Diluted Shares Outstanding | -0.83% | -0.44% | -0.08% | -0.37% | -0.14% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |